SECsense Logo

BridgeBio Pharma, Inc. 8-K Filing Report: Key Updates for Investors

$BBIO
Form 8-K
Filed on: 2025-02-20
Source
BridgeBio Pharma, Inc. 8-K Filing Report: Key Updates for Investors

Based on the provided XML excerpt from a financial report, here are the key pieces of information extracted and analyzed:

  1. Entity Information:
  • Company Name: BridgeBio Pharma, Inc.
  • CIK (Central Index Key): 0001743881
  • Exchange: NASDAQ
  • Ticker Symbol: BBIO
  • Incorporation State: Delaware (DE)
  • Employer Identification Number (EIN): 84-1850815
  • Address: 3160 Porter Dr., Suite 250, Palo Alto, CA 94304
  • Contact Number: 650-391-9740
  1. Filing Information:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: February 20, 2025
  1. Common Stock Details:
  • Par Value: $0.001 per share
  1. Reporting Period:
  • Start Date: February 20, 2025
  • End Date: February 20, 2025
  • The context indicates that this report pertains to a specific day rather than a traditional quarterly or annual reporting period.

Insights:

  • The filing is an 8-K, which usually signifies that the company is reporting significant events or changes that may be important for investors. The specific nature of the events would need to be provided in the body of the 8-K filing.
  • The inclusion of the common stock par value indicates that the company is publicly traded and may be relevant for understanding stockholder equity and corporate finance decisions.
  • The report is very recent and suggests that it may contain timely information that could impact the stock price or investor decision-making.

For a complete understanding of the implications of this filing, further details from the body of the 8-K would be necessary, especially regarding the specific events being reported.